JP2008540363A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008540363A5 JP2008540363A5 JP2008509380A JP2008509380A JP2008540363A5 JP 2008540363 A5 JP2008540363 A5 JP 2008540363A5 JP 2008509380 A JP2008509380 A JP 2008509380A JP 2008509380 A JP2008509380 A JP 2008509380A JP 2008540363 A5 JP2008540363 A5 JP 2008540363A5
- Authority
- JP
- Japan
- Prior art keywords
- helix
- nucleic acid
- nucleotides
- segmental
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002773 nucleotide Substances 0.000 claims 36
- 125000003729 nucleotide group Chemical group 0.000 claims 36
- 239000000203 mixture Substances 0.000 claims 22
- 108020004707 nucleic acids Proteins 0.000 claims 16
- 102000039446 nucleic acids Human genes 0.000 claims 16
- 150000007523 nucleic acids Chemical class 0.000 claims 16
- NPOAOTPXWNWTSH-UHFFFAOYSA-N 3-hydroxy-3-methylglutaric acid Chemical group OC(=O)CC(O)(C)CC(O)=O NPOAOTPXWNWTSH-UHFFFAOYSA-N 0.000 claims 13
- 102000009012 HMGA Proteins Human genes 0.000 claims 13
- 108010049069 HMGA Proteins Proteins 0.000 claims 13
- 230000027455 binding Effects 0.000 claims 12
- 239000003981 vehicle Substances 0.000 claims 12
- 238000005192 partition Methods 0.000 claims 9
- 102000027411 intracellular receptors Human genes 0.000 claims 8
- 108091008582 intracellular receptors Proteins 0.000 claims 8
- 206010028980 Neoplasm Diseases 0.000 claims 7
- 108091027076 Spiegelmer Proteins 0.000 claims 7
- 210000004027 cell Anatomy 0.000 claims 7
- 229920002873 Polyethylenimine Polymers 0.000 claims 6
- 230000003834 intracellular effect Effects 0.000 claims 6
- 108700039142 HMGA1a Proteins 0.000 claims 5
- 102000049983 HMGA1a Human genes 0.000 claims 5
- 108700039144 HMGA1b Proteins 0.000 claims 5
- 108700039143 HMGA2 Proteins 0.000 claims 5
- 102100029009 High mobility group protein HMG-I/HMG-Y Human genes 0.000 claims 5
- 102100028999 High mobility group protein HMGI-C Human genes 0.000 claims 5
- 101150073387 Hmga2 gene Proteins 0.000 claims 5
- 101000986380 Homo sapiens High mobility group protein HMG-I/HMG-Y Proteins 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 238000009396 hybridization Methods 0.000 claims 5
- 238000000034 method Methods 0.000 claims 5
- 102000052510 DNA-Binding Proteins Human genes 0.000 claims 4
- 108700020911 DNA-Binding Proteins Proteins 0.000 claims 4
- 108091023040 Transcription factor Proteins 0.000 claims 4
- 102000040945 Transcription factor Human genes 0.000 claims 4
- 206010061289 metastatic neoplasm Diseases 0.000 claims 3
- 238000012986 modification Methods 0.000 claims 3
- 230000004048 modification Effects 0.000 claims 3
- 206010003210 Arteriosclerosis Diseases 0.000 claims 2
- 206010005969 Bone giant cell tumour Diseases 0.000 claims 2
- 208000011691 Burkitt lymphomas Diseases 0.000 claims 2
- 208000021994 Diffuse astrocytoma Diseases 0.000 claims 2
- 206010024612 Lipoma Diseases 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 206010027476 Metastases Diseases 0.000 claims 2
- 206010029260 Neuroblastoma Diseases 0.000 claims 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims 2
- 206010046798 Uterine leiomyoma Diseases 0.000 claims 2
- 208000036142 Viral infection Diseases 0.000 claims 2
- 208000028435 angiomyxoma Diseases 0.000 claims 2
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 2
- 201000011143 bone giant cell tumor Diseases 0.000 claims 2
- 210000000481 breast Anatomy 0.000 claims 2
- 210000001072 colon Anatomy 0.000 claims 2
- 208000016018 endometrial polyp Diseases 0.000 claims 2
- 201000001169 fibrillary astrocytoma Diseases 0.000 claims 2
- 201000010260 leiomyoma Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 230000009401 metastasis Effects 0.000 claims 2
- 230000001394 metastastic effect Effects 0.000 claims 2
- 208000009091 myxoma Diseases 0.000 claims 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 2
- 210000000496 pancreas Anatomy 0.000 claims 2
- 210000004786 perivascular cell Anatomy 0.000 claims 2
- 208000004333 pleomorphic adenoma Diseases 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 210000002307 prostate Anatomy 0.000 claims 2
- 210000003079 salivary gland Anatomy 0.000 claims 2
- 230000011218 segmentation Effects 0.000 claims 2
- 201000000849 skin cancer Diseases 0.000 claims 2
- 210000002784 stomach Anatomy 0.000 claims 2
- 210000001685 thyroid gland Anatomy 0.000 claims 2
- 201000007954 uterine fibroid Diseases 0.000 claims 2
- 206010046811 uterine polyp Diseases 0.000 claims 2
- 230000009385 viral infection Effects 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 claims 1
- 201000005262 Chondroma Diseases 0.000 claims 1
- 229920000858 Cyclodextrin Polymers 0.000 claims 1
- 208000002927 Hamartoma Diseases 0.000 claims 1
- 108010076504 Protein Sorting Signals Proteins 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 208000016160 chondroid hamartoma Diseases 0.000 claims 1
- 229940097362 cyclodextrins Drugs 0.000 claims 1
- 239000000412 dendrimer Substances 0.000 claims 1
- 229920000736 dendritic polymer Polymers 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000003596 drug target Substances 0.000 claims 1
- 238000004520 electroporation Methods 0.000 claims 1
- 230000001159 endocytotic effect Effects 0.000 claims 1
- 230000000799 fusogenic effect Effects 0.000 claims 1
- 238000011534 incubation Methods 0.000 claims 1
- 239000002502 liposome Substances 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 239000000693 micelle Substances 0.000 claims 1
- 239000011859 microparticle Substances 0.000 claims 1
- 239000002105 nanoparticle Substances 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 230000035939 shock Effects 0.000 claims 1
- 150000003384 small molecules Chemical class 0.000 claims 1
- 238000002604 ultrasonography Methods 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102005020874 | 2005-05-04 | ||
| PCT/EP2006/004180 WO2006117217A2 (de) | 2005-05-04 | 2006-05-04 | Neue verwendung von spiegelmeren |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013129800A Division JP5766750B2 (ja) | 2005-05-04 | 2013-06-20 | シュピーゲルマーの新規な使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008540363A JP2008540363A (ja) | 2008-11-20 |
| JP2008540363A5 true JP2008540363A5 (enExample) | 2009-06-25 |
Family
ID=36928624
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008509380A Pending JP2008540363A (ja) | 2005-05-04 | 2006-05-04 | シュピーゲルマーの新規な使用 |
| JP2013129800A Expired - Fee Related JP5766750B2 (ja) | 2005-05-04 | 2013-06-20 | シュピーゲルマーの新規な使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013129800A Expired - Fee Related JP5766750B2 (ja) | 2005-05-04 | 2013-06-20 | シュピーゲルマーの新規な使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US8497250B2 (enExample) |
| EP (2) | EP1877069A2 (enExample) |
| JP (2) | JP2008540363A (enExample) |
| KR (2) | KR101418369B1 (enExample) |
| CN (2) | CN104293780A (enExample) |
| AU (1) | AU2006243334A1 (enExample) |
| BR (1) | BRPI0610367A2 (enExample) |
| CA (1) | CA2607185A1 (enExample) |
| MX (1) | MX2007013760A (enExample) |
| SG (1) | SG161311A1 (enExample) |
| WO (1) | WO2006117217A2 (enExample) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9492400B2 (en) | 2004-11-04 | 2016-11-15 | Massachusetts Institute Of Technology | Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals |
| US9267937B2 (en) | 2005-12-15 | 2016-02-23 | Massachusetts Institute Of Technology | System for screening particles |
| WO2008105773A2 (en) | 2006-03-31 | 2008-09-04 | Massachusetts Institute Of Technology | System for targeted delivery of therapeutic agents |
| JP5630998B2 (ja) | 2006-05-15 | 2014-11-26 | マサチューセッツ インスティテュート オブ テクノロジー | 機能的粒子のためのポリマー |
| WO2007150030A2 (en) | 2006-06-23 | 2007-12-27 | Massachusetts Institute Of Technology | Microfluidic synthesis of organic nanoparticles |
| US9217129B2 (en) | 2007-02-09 | 2015-12-22 | Massachusetts Institute Of Technology | Oscillating cell culture bioreactor |
| WO2008124639A2 (en) | 2007-04-04 | 2008-10-16 | Massachusetts Institute Of Technology | Poly (amino acid) targeting moieties |
| BRPI0817664A2 (pt) | 2007-10-12 | 2015-03-24 | Massachusetts Inst Technology | Nanopartículas, método para preparar nanopartículas e método para tratar terapeuticamente ou profilaticamente um indivíduo |
| US8277812B2 (en) | 2008-10-12 | 2012-10-02 | Massachusetts Institute Of Technology | Immunonanotherapeutics that provide IgG humoral response without T-cell antigen |
| US8343497B2 (en) | 2008-10-12 | 2013-01-01 | The Brigham And Women's Hospital, Inc. | Targeting of antigen presenting cells with immunonanotherapeutics |
| US8343498B2 (en) | 2008-10-12 | 2013-01-01 | Massachusetts Institute Of Technology | Adjuvant incorporation in immunonanotherapeutics |
| US8591905B2 (en) | 2008-10-12 | 2013-11-26 | The Brigham And Women's Hospital, Inc. | Nicotine immunonanotherapeutics |
| WO2010138193A2 (en) | 2009-05-27 | 2010-12-02 | Selecta Biosciences, Inc. | Targeted synthetic nanocarriers with ph sensitive release of immunomodulatory agents |
| US20130149314A1 (en) * | 2010-02-09 | 2013-06-13 | Jörn Bullerdiek | p19Arf, HMGA2 and MDM2 For Use in the Diagnosis and Treatment of Aberrant Cell Growth |
| WO2011131371A1 (en) | 2010-04-21 | 2011-10-27 | Noxxon Pharma Ag | Lipid binding nucleic acids |
| US20110293700A1 (en) | 2010-05-26 | 2011-12-01 | Selecta Biosciences, Inc. | Nanocarrier compositions with uncoupled adjuvant |
| CN102375064A (zh) * | 2010-08-26 | 2012-03-14 | 杭州华得森生物技术有限公司 | 用酶联免疫法检测人体中hmga2含量的体外诊断试剂盒 |
| DE102010056610A1 (de) * | 2010-12-31 | 2012-07-05 | Volker A. Erdmann | Pharmazeutische Zusammensetzung enthaltend L-DNA |
| CN109172819A (zh) | 2011-07-29 | 2019-01-11 | 西莱克塔生物科技公司 | 产生体液和细胞毒性t淋巴细胞（ctl）免疫应答的合成纳米载体 |
| JP2014533098A (ja) * | 2011-10-21 | 2014-12-11 | ノクソン・ファルマ・アクチエンゲゼルシャフト | グルカゴン結合核酸 |
| SG11201403769YA (en) * | 2012-01-10 | 2014-07-30 | Noxxon Pharma Ag | Nucleic acids specifically binding cgrp |
| CN103566377A (zh) | 2012-07-18 | 2014-02-12 | 上海博笛生物科技有限公司 | 癌症的靶向免疫治疗 |
| US9233119B2 (en) * | 2012-09-27 | 2016-01-12 | Miami University | Use of HGMA-targeted phosphorothioate DNA aptamers to suppress carcinogenic activity and increase sensitivity to chemotherapy agents in human cancer cells |
| WO2014193964A2 (en) * | 2013-05-28 | 2014-12-04 | Marsha Rosner | Prognostic and predictive breast cancer signature |
| US10679730B2 (en) | 2013-05-28 | 2020-06-09 | The University Of Chicago | Prognostic and predictive breast cancer signature |
| CA2936377A1 (en) | 2014-01-10 | 2015-07-16 | Shanghai Birdie Biotech, Inc. | Compounds and compositions for treating egfr expressing tumors |
| EP4001311B1 (en) | 2014-07-09 | 2025-11-05 | Birdie Biopharmaceuticals Inc. | Anti-pd-l1/pd-1 combinations for treating tumors |
| CN112546231A (zh) | 2014-07-09 | 2021-03-26 | 博笛生物科技有限公司 | 用于治疗癌症的联合治疗组合物和联合治疗方法 |
| KR101755617B1 (ko) | 2014-07-23 | 2017-07-10 | 한국과학기술연구원 | 삼차원 자기조립 핵산 나노입자 구조를 갖는 약물전달체 |
| CN112546238A (zh) | 2014-09-01 | 2021-03-26 | 博笛生物科技有限公司 | 用于治疗肿瘤的抗-pd-l1结合物 |
| EP3233174B1 (en) * | 2014-12-19 | 2021-03-31 | Kemin Industries, Inc. | Intraocular delivery of bioactive molecules using iontophoresis |
| CA2985818A1 (en) | 2015-05-31 | 2016-12-08 | Curegenix Corporation | Combination compositions comprising an antagonist of porcupine and a pd-l/pd-1 axis antagonist for immunotherapy |
| EP3347051A4 (en) | 2015-09-10 | 2019-04-24 | Affigen, Inc. | SEQUENCING SELECTING TUMOR THEROSTICAS |
| DE17829597T1 (de) * | 2016-11-30 | 2019-12-05 | Noxxon Pharma Ag | Verfahren zur polyalkoxylierung von nukleinsäuren zur rückgewinnung und wiederverwendung einer überschüssigen polyalkoxylierungsreagenz |
| US20220033813A1 (en) * | 2018-09-11 | 2022-02-03 | The Texas A&M University System | L-oligonucleotide inhibitors of polycomb repressive complex 2 (prc2) |
| CN115997124A (zh) * | 2020-04-30 | 2023-04-21 | 维兰尼迪科技有限责任公司 | 用于检测生物或化学实体或事件的分子导线 |
| CN112725438B (zh) * | 2021-02-05 | 2023-08-22 | 深圳市宝安区妇幼保健院 | 子宫内膜息肉甲基化标志物组合、检测试剂盒及应用 |
| CN114807183B (zh) * | 2021-12-06 | 2023-06-02 | 西藏自治区农牧科学院农业研究所 | 一种青稞矢车菊素氧甲基转移酶基因的新用途 |
| CN118311277B (zh) * | 2024-06-11 | 2024-12-31 | 北京卫未科学技术有限公司 | 一种用于癌症早筛和辅助诊断的试剂盒及其应用 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5622828A (en) * | 1990-06-11 | 1997-04-22 | Nexstar Pharmaceuticals, Inc. | High-affinity oligonucleotide ligands to secretory phospholipase A2 (sPLA2) |
| EP1793006A3 (en) * | 1993-09-08 | 2007-08-22 | Gilead Sciences, Inc. | Nucleic acid ligands and improved methods for producing the same |
| DE69638099D1 (de) * | 1995-05-04 | 2010-01-28 | Gilead Sciences Inc | Nukleinsäureligand-komplexe |
| US5780611A (en) * | 1995-09-15 | 1998-07-14 | Ramareddy Venkata Guntaka | Oligomers which inhibit expression of collagen genes |
| US6171779B1 (en) | 1996-07-12 | 2001-01-09 | University Of Medicine & Dentistry Of New Jersey | HMGI proteins in cancer |
| JP2001504448A (ja) * | 1996-08-30 | 2001-04-03 | フュルステ，イェンス，ペーター | 核酸の鏡面対称選択および進化 |
| DE19726186A1 (de) * | 1997-06-20 | 1998-12-24 | Boehringer Ingelheim Int | Komplexe für den Transport von Nukleinsäure in höhere eukaryotische Zellen |
| JP2004510829A (ja) * | 2000-10-09 | 2004-04-08 | バイエル アクチェンゲゼルシャフト | 核酸を細胞内に転移させるための複合体 |
| DE10118452A1 (de) * | 2001-04-12 | 2002-10-31 | Joern Bullerdiek | Nukleinsäuresequenzen von Hyperplasien und Tumoren der Schilddrüse |
| ES2346640T4 (es) * | 2001-10-26 | 2011-04-26 | Noxxon Pharma Ag | Ácido l-nucleico modificado. |
| WO2003051383A2 (de) * | 2001-12-19 | 2003-06-26 | Alcedo Biotech Gmbh | Verwendung von hmgb-proteinen und dafür codierenden nukleinsäuren |
| DE10211558A1 (de) * | 2002-03-15 | 2003-10-09 | Noxxon Pharma Ag | Neue Formen RNAi |
| WO2003094973A1 (de) * | 2002-05-08 | 2003-11-20 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Mittel und verfahren zum transport von biologisch aktiven molekülen in zellen |
| US7250496B2 (en) * | 2002-11-14 | 2007-07-31 | Rosetta Genomics Ltd. | Bioinformatically detectable group of novel regulatory genes and uses thereof |
| WO2004061456A2 (de) * | 2003-01-03 | 2004-07-22 | Alcedo Biotech Gmbh | Verwendungen von hmgb, hmgn, hmga proteinen |
| KR20060015505A (ko) * | 2003-04-13 | 2006-02-17 | 엔존 파마슈티컬즈, 인코포레이티드 | 올리고뉴클레오타이드 전구약물 |
| EP1628636A1 (de) * | 2003-05-09 | 2006-03-01 | Novosom AG | Injizierbare liposomale depots zum wirkstoffdelivery |
| CA2526853A1 (en) * | 2003-05-23 | 2005-03-03 | Board Of Regents - The University Of Texas System | Structure based and combinatorially selected oligonucleoside phosphorothioate and phosphorodithioate aptamer targeting ap-1 transcription factors |
| US7727969B2 (en) * | 2003-06-06 | 2010-06-01 | Massachusetts Institute Of Technology | Controlled release nanoparticle having bound oligonucleotide for targeted delivery |
| WO2005072703A2 (en) * | 2004-01-26 | 2005-08-11 | Control Delivery Systems, Inc. | Controlled and sustained delivery of nucleic acid-based therapeutic agents |
| WO2006069782A2 (en) * | 2004-12-27 | 2006-07-06 | Silence Therapeutics Ag. | Lipid complexes coated with peg and their use |
-
2006
- 2006-05-04 CA CA002607185A patent/CA2607185A1/en not_active Abandoned
- 2006-05-04 MX MX2007013760A patent/MX2007013760A/es unknown
- 2006-05-04 BR BRPI0610367-7A patent/BRPI0610367A2/pt not_active IP Right Cessation
- 2006-05-04 KR KR1020077025457A patent/KR101418369B1/ko not_active Expired - Fee Related
- 2006-05-04 EP EP06742799A patent/EP1877069A2/de not_active Ceased
- 2006-05-04 CN CN201410395203.5A patent/CN104293780A/zh active Pending
- 2006-05-04 SG SG201002837-1A patent/SG161311A1/en unknown
- 2006-05-04 JP JP2008509380A patent/JP2008540363A/ja active Pending
- 2006-05-04 CN CN200680024585.4A patent/CN101217967B/zh not_active Expired - Fee Related
- 2006-05-04 WO PCT/EP2006/004180 patent/WO2006117217A2/de not_active Ceased
- 2006-05-04 KR KR1020147008135A patent/KR101418367B1/ko not_active Expired - Fee Related
- 2006-05-04 US US11/913,526 patent/US8497250B2/en not_active Expired - Fee Related
- 2006-05-04 AU AU2006243334A patent/AU2006243334A1/en not_active Abandoned
- 2006-05-04 EP EP09016125A patent/EP2206501A3/de not_active Withdrawn
-
2013
- 2013-06-20 JP JP2013129800A patent/JP5766750B2/ja not_active Expired - Fee Related
- 2013-07-30 US US13/953,797 patent/US9074214B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008540363A5 (enExample) | ||
| KR102262260B1 (ko) | 엔도좀 탈출능을 갖는 펩티드 핵산 복합체 및 이의 용도 | |
| JP6818889B2 (ja) | 細胞透過性が向上したペプチド核酸複合体およびそれを含む薬学的組成物 | |
| JP6060178B2 (ja) | 高効率のナノ粒子型二本鎖オリゴｒｎａ構造体およびその製造方法 | |
| KR101867414B1 (ko) | 호흡기 질환 연관 유전자 특이적 siRNA, 그러한 siRNA를 포함하는 이중나선 올리고 RNA 구조체 및 이를 포함하는 호흡기 질환 예방 또는 치료용 조성물 | |
| US9289505B2 (en) | Compositions and methods for delivering nucleic acid molecules and treating cancer | |
| JP5906327B2 (ja) | 磁性ナノ粒子−ＳＡＭｉＲＮＡ複合体およびその製造方法 | |
| US20200360296A1 (en) | Nanoparticle-hydrogel composite for nucleic acid molecule delivery | |
| EP2190482A2 (en) | Targeted block copolymer micelles | |
| Golan et al. | Conjugates of HA2 with octaarginine-grafted HPMA copolymer offer effective siRNA delivery and gene silencing in cancer cells | |
| BR112016000160B1 (pt) | estrutura de oligonucleotídeo tipo nanopartícula melhorada tendo alta eficiência e método para a preparação da mesma | |
| US10155946B2 (en) | Particle-nucleic acid conjugates and therapeutic uses related thereto | |
| CN114364404A (zh) | 寡核苷酸-聚合物多手臂偶联物以及使用方法 | |
| US11008575B2 (en) | DNA aptamers against cancer and uses thereof in delivery of therapy and diagnosis of cancer | |
| KR101715228B1 (ko) | 뎅기 바이러스 특이적 siRNA, 그러한 siRNA 를 포함하는 이중나선 올리고 RNA 구조체 및 이를 포함하는 뎅기 바이러스 증식 억제용 조성물 | |
| US20120220647A1 (en) | Nano-hybrid of targetable sirna-layered inorganic hydroxide, manufacturing method thereof, and pharmaceutical composition for treating tumor comprising the nano-hybrid | |
| JP5510808B2 (ja) | 有機ナノチューブからなる核酸導入剤 | |
| JP2003526692A (ja) | ポリヌクレオチド組成物 | |
| CN104189920A (zh) | 逆转肿瘤多药耐药的基因组合物h-R3/PAMAM G5/MDR1 siRNA及其应用 | |
| JP2025512450A (ja) | アプタマー、複合体及び組成物並びに製造方法及び使用 | |
| WO2016109522A1 (en) | Particle-nucleic acid conjugates and therapeutic uses related thereto | |
| KR101722948B1 (ko) | 리간드가 결합된 이중나선 올리고 ｒｎａ 구조체 및 그 제조방법 | |
| Mohammed-Saeid et al. | Design and Evaluation of Gemini Surfactant-Based Lipoplexes Modified with Cell-Binding Peptide for Targeted Gene Therapy | |
| Chen | Macrophage targeting using nanotechnology for HIV therapy | |
| Dube | Formulation, Characterization and Evaluation of Nanoparticulate Therapeutic Systems for Targeting Brain Tumors |